Bioheart, Inc. is a development-stage, biotechnology company. The Company focuses on the discovery, development and commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. MyoCell is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. The Company�s clinical trials of MyoCell include the SEISMIC Trial, which completed a 40-patient, randomized, multicenter, controlled, Phase II-a study conducted in Europe; the MYOHEART Trial, a completed 20-patient, multicenter, Phase I dose-escalation trial conducted in the United States, and the MARVEL Trial, a 330-patient, multicenter Phase II/III trial of MyoCell in North America and Europe.